Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention

References

• Burger HG, Dudley EC, Robertson DM, Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Horm Res 2002;57:257–75
   PubMedGoogle Scholar
• Gold EB, Colvin A, Avis N, . Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women’s Health Across the Nation. Am J Public Health 2006;96:1226–35
   PubMed Web of Science ®Google Scholar
• Col NF, Guthrie JR, Politi M, Dennerstein L. Duration of vasomotor symptoms in middle-aged women: a longitudinal study. Menopause 2009;16:453–7
   PubMed Web of Science ®Google Scholar
• Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008;15: 661–6
   PubMed Web of Science ®Google Scholar
• Versi E, Harvey MA, Cardozo L, Brincat M, Studd JW. Urogenital prolapse and atrophy at menopause: a prevalence study. Int Urogynecol J Pelvic Floor Dysfunct 2001;12: 107–10
   PubMed Web of Science ®Google Scholar
• Burger HG. The endocrinology of the menopause. Maturitas 1996;23:129–36
   PubMed Web of Science ®Google Scholar
• Riggs BL, Khosla S, Melton LJ III. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998;13: 763–73
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation.Fast facts on osteoporosis. http://www.nof.org/node/40 [serial online]; Accessed November 17, 2011
   Google Scholar
• North American Menopause Society.Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242–55
   PubMed Web of Science ®Google Scholar
• Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274–7
   PubMed Web of Science ®Google Scholar
• Weiderpass E, Adami HO, Baron JA, . Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131–7
   PubMed Web of Science ®Google Scholar
• Rolnick SJ, Kopher RA, DeFor TA, Kelley ME. Hormone use and patient concerns after the findings of the Women’s Health Initiative. Menopause 2005;12:399–404
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Kharode Y, Bodine PV, Miller CP, Lyttle CR, Komm BS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008;149:6084–91
   PubMed Web of Science ®Google Scholar
• Berrodin TJ, Chang KC, Komm BS, Freedman LP, Nagpal S. Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene–conjugated estrogens combination. Mol Endocrinol 2009;23:75–85
   Google Scholar
• Chang KCN, Wang Y, Bodine PV, Nagpal S, Komm BS. Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. J Steroid Biochem Mol Biol 2010;118:117–24
   PubMed Web of Science ®Google Scholar
• Peano BJ, Crabtree JS, Komm BS, Winneker RC, Harris HA. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 2009;150:1897–903
   PubMed Web of Science ®Google Scholar
• Komm BS, Vlasseros F, Samadfam R, Chouinard L, Smith SY. Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats. Bone 2011;49:376–86
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/ conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045–52
   PubMed Web of Science ®Google Scholar
• Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009;92:1039–44
   PubMed Web of Science ®Google Scholar
• Lobo RA, Pinkerton JV, Gass ML, . Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025–38
   PubMed Web of Science ®Google Scholar
• Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018–24
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16:1116–24
   PubMed Web of Science ®Google Scholar
• Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas 2009;63:329–35
   PubMed Web of Science ®Google Scholar
• Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17:281–9
   PubMed Web of Science ®Google Scholar
• Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/ conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric 2010;13:132–40
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Pan K, Pickar J, Mirkin S. Effects of bazedoxifene/conjugated estrogens (BZA/CE) on hot flushes in postmenopausal women: effect of timing of therapy initiation. Endocr Rev 2010;31(3 Suppl 1):S1304
   Google Scholar
• Mirkin S, Pan K, Chines AA. Effects of body mass index and years since menopause on the efficacy of bazedoxifene/conjugated estrogens (BZA/CE) on vasomotor symptoms. Menopause 2010;17:1234–5
   Web of Science ®Google Scholar
• Pinkerton JV, Chines AA, Racketa J, Mirkin S. Menopause- related quality of life and satisfaction in postmenopausal women treated with bazedoxifene/conjugated estrogens (BZA/CE). Menopause 2010;17:1219
   Web of Science ®Google Scholar
• Pinkerton JV, Racketa J, Shi H, Chines AA, Mirkin S. Evaluation of secondary outcomes in postmenopausal women treated with bazedoxifene/conjugated estrogen by years since menopause. Climacteric 2011;14(Suppl 1):172 (Abstr)
   Google Scholar
• Pinkerton JV, Chines AA, Racketa J, Mirkin S. Bazedoxifene/conjugated estrogens (BZA/CE): effect on sleep parameters in postmenopausal women. Menopause 2010;17:1237–8
   Web of Science ®Google Scholar
• Pinkerton JV, Taylor H, Pan K, Chines A, Mirkin S. Breast parameters with bazedoxifene/conjugated estrogens in randomized, controlled trials of postmenopausal women. Menopause 2010;17:1221–2
   Web of Science ®Google Scholar
• Pinkerton JA, Constantine GD, Komm BS, Yu H, Pickar JH. Breast effects of bazedoxifene/conjugated estrogens in a randomized, controlled trial of postmenopausal women. Poster presented at the 19th Annual Meeting of the North American Menopause Society, September 24–27, 2008, Lake Buena Vista, FL, USA
   Google Scholar
• Harvey JA, Pinkerton JV, Baracat EC, Shi H, Mirkin S, Chines AA. Evaluation of changes in mammographic breast density associated with bazedoxifene/conjugated estrogens in postmenopausal women. Endocr Rev 2011;32:1–79
   Google Scholar
• Gaspard UJ, Gottal JM, van den Brule FA. Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects. Maturitas 1995;21:171–8
   PubMed Web of Science ®Google Scholar